HEOR Online Training Modules for Your Team

For busy professionals at all experience levels

Modules focus on Health Economic & Outcomes Research (HEOR) concepts and trends

EMPOWER your team to

• Engage colleagues in HEOR discussions
• Interpret HEOR studies
• Communicate HEOR data more effectively
• Understand how analyses are used by decision makers
• Become better consumers of pharmacoeconomic literature
Each Module Contains

- Learning objectives
- 1-hour videos presented in short segments
- Interactive video questions
- Presentation slides
- Dynamic self-assessment quizzes
- Interactive games

For more information
Jason Hurwitz, PhD
Assistant Director
Center for Health Outcomes & Pharmacoeconomic Research
University of Arizona College of Pharmacy
hurwitz@pharmacy.arizona.edu
520-626-8889
Select Modules that Benefit Your Team

Pharmacoeconomic principles

- Define pharmacoeconomic research and how it’s used
- Identify five ways a medication can be considered “cost-effective”
- Distinguish among types of costs (direct medical, direct non-medical, indirect, intangible)
- Describe types of outcomes (e.g., surrogate vs final, economic, clinical, patient reported) and how they are incorporated into cost-effectiveness analyses
- Recognize how to interpret a cost-effectiveness plane
- Describe various study perspectives
- Identify the importance of sensitivity analysis

Pharmacoeconomic methodology

- Identify differences among various pharmacoeconomic methodologies, such as cost-of-illness analysis, cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis
- Calculate the incremental cost-effectiveness for one medication over another
- Describe how utility values are used to calculate a quality-adjusted life year
- Discuss the difference between average cost-effectiveness ratios and incremental cost-effectiveness ratios
- Describe the advantages of using cost-effectiveness acceptability curves

Patient-reported outcomes (PRO) assessment

- Define patient-reported outcomes (PROs) and when they should be used
- Identify types of instruments used to measure PROs, including generic and disease-specific tools
- Describe examples of commonly used PRO instruments, including the SF-36 Health Survey and the EQ-5D
- Discuss the importance of measuring what is important to the patient
- List examples of PRO label claims
- Outline recommendations in the FDA PRO Guidance
- Explain how a PRO instrument can be considered valid and reliable
Budget impact analysis
• Define components included in budget impact analyses
• Discuss ISPOR Principles of Good Practice for Budget Impact Analysis
• Describe examples of published budget impact analyses
• Identify key questions that are raised about budget impact analyses
• Outline differences between budget impact and pharmacoeconomic analyses
• Discuss ways to best communicate budget impact models with end users

Real world evidence – overview of methods
• Clarify definitions and policy issues, and why RWE has received so much attention from various stakeholders
• Describe different types of RWE studies including associated advantages and disadvantages
• Differentiate observational study designs including cohort, case control, and pragmatic trials
• Discuss statistical techniques used in observational research such as propensity score matching
• Compare and contrast various tools available for evaluating observational studies

Real world data sources and use in studies
• Outline definitions and uses of primary, secondary, and tertiary data sources
• Describe common sources and examples of observational data (registries, surveys, administrative claims and electronic medical records databases) used to generate RWE, including their advantages and limitations
• Identify common sources and examples of costs and outcomes data used to populate pharmacoeconomic analyses, including their advantages and limitations

Pay for performance measures (Risk-based contracting)
• Describe key characteristics of performance-based risk-sharing (PBRS) agreements and why they are becoming so popular
• Discuss use of agreements in the US, including types and therapeutic areas
• Identify good practice recommendations issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) PBRS Task Force
• Outline specific examples of PBRS agreements
• List benefits, challenges, and potential barriers for performance-based risk-sharing agreements
New Modules Coming Soon

The following modules are currently under development and will soon be available

Decision analysis
- Describe the steps in building a decision tree
- Illustrate how the data elements entered into a decision tree should be analyzed
- Build a decision tree using Excel software
- Interpret findings from the decision analysis

Markov models
- Differentiate between decision trees and Markov models
- Identify disease conditions where a Markov analysis is preferred to a decision tree
- Interpret Markov structures and results presented in publications
- Build a Markov model using Excel software

Value frameworks
- Describe initiatives by professional societies to create value frameworks
- Discuss limitations of value frameworks
- Explain the process used by the Institute for Clinical and Economic Review (ICER) to assess product value
- Discuss potential reasons why ICER results may not be useful to payers for coverage decisions

Consider combining with customized live program
- Reinforce online modules with interactive workshops and discussions
- Enhance with additional topics tailored for your team
- Choose from a wide array of sessions focusing on additional tools, concepts, and methods
- Visit Tucson or our faculty will come to you